Literature DB >> 29434904

Epigenetic actions of environmental factors and promising drugs for cancer therapy.

Zhong-Tian Bai1,2, Bing Bai1,2, Jun Zhu3, Cui-Xia Di4, Xun Li1,2, Wen-Ce Zhou1,2.   

Abstract

Carcinogenesis is known to be primarily associated with gene mutations. Recently, increasing evidence has suggested that epigenetic events also serve crucial roles in tumor etiology. Environmental factors, including nutrition, toxicants and ethanol, are involved in carcinogenesis through inducing epigenetic modifications, such as DNA methylation, histone deacetylase and miRNA regulation. Studying epigenetic mechanisms has facilitated the development of early diagnostic strategies and potential therapeutic avenues. Modulation at the epigenetic level, including reversing epigenetic modifications using targeted drugs, has demonstrated promise in cancer therapy. Therefore, identifying novel epigenetic biomarkers and therapeutic targets has potential for the future of cancer therapy. The present review discusses the environmental factors involved in epigenetic modifications and potential drug candidates for cancer therapy.

Entities:  

Keywords:  cancer therapy; environmental factor; epigenetic modification; promising drug

Year:  2017        PMID: 29434904      PMCID: PMC5776905          DOI: 10.3892/ol.2017.7597

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  80 in total

Review 1.  KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.

Authors:  Tamara Maes; Cristina Mascaró; Alberto Ortega; Serena Lunardi; Filippo Ciceri; Tim C P Somervaille; Carlos Buesa
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

Review 2.  Romidepsin: a novel histone deacetylase inhibitor for cancer.

Authors:  Erin M Bertino; Gregory A Otterson
Journal:  Expert Opin Investig Drugs       Date:  2011-06-24       Impact factor: 6.206

3.  miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A.

Authors:  Xufu Wei; Tingxiu Xiang; Guosheng Ren; Cui Tan; Rui Liu; Xiao Xu; Zhongjun Wu
Journal:  Cell Signal       Date:  2012-11-01       Impact factor: 4.315

4.  Assay development for histone methyltransferases.

Authors:  Kurumi Y Horiuchi; Mia M Eason; Joseph J Ferry; Jamie L Planck; Colin P Walsh; Robert F Smith; Konrad T Howitz; Haiching Ma
Journal:  Assay Drug Dev Technol       Date:  2013-04-04       Impact factor: 1.738

5.  A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.

Authors:  I Garrido-Laguna; K A McGregor; M Wade; J Weis; W Gilcrease; L Burr; R Soldi; L Jakubowski; C Davidson; G Morrell; J D Olpin; K Boucher; D Jones; S Sharma
Journal:  Invest New Drugs       Date:  2013-03-17       Impact factor: 3.850

Review 6.  The developmental environment, epigenetic biomarkers and long-term health.

Authors:  K M Godfrey; P M Costello; K A Lillycrop
Journal:  J Dev Orig Health Dis       Date:  2015-05-28       Impact factor: 2.401

7.  EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.

Authors:  Jing Cui; Wendong Sun; Xuexi Hao; Minli Wei; Xiaonan Su; Yajing Zhang; Ling Su; Xiangguo Liu
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

8.  Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells.

Authors:  Zhi Gao; Zhidong Xu; Ming-Szu Hung; Yu-Ching Lin; Tianyou Wang; Min Gong; Xiuyi Zhi; David M Jablons; Liang You
Journal:  Oncol Rep       Date:  2009-12       Impact factor: 3.906

9.  Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors.

Authors:  Sumit S Mahajan; Michele Scian; Smitha Sripathy; Jeff Posakony; Uyen Lao; Taylor K Loe; Vid Leko; Angel Thalhofer; Aaron D Schuler; Antonio Bedalov; Julian A Simon
Journal:  J Med Chem       Date:  2014-04-15       Impact factor: 7.446

Review 10.  Epigenetic modulators as therapeutic targets in prostate cancer.

Authors:  Inês Graça; Eva Pereira-Silva; Rui Henrique; Graham Packham; Simon J Crabb; Carmen Jerónimo
Journal:  Clin Epigenetics       Date:  2016-09-15       Impact factor: 6.551

View more
  2 in total

Review 1.  The World of Oral Cancer and Its Risk Factors Viewed from the Aspect of MicroRNA Expression Patterns.

Authors:  Ovidiu Aghiorghiesei; Oana Zanoaga; Andreea Nutu; Cornelia Braicu; Radu Septimiu Campian; Ondine Lucaciu; Ioana Berindan Neagoe
Journal:  Genes (Basel)       Date:  2022-03-26       Impact factor: 4.141

2.  Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target.

Authors:  Chin-Sheng Hung; Sheng-Chao Wang; Yi-Ting Yen; Tzong-Huei Lee; Wu-Che Wen; Ruo-Kai Lin
Journal:  Int J Mol Sci       Date:  2018-10-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.